Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 436 participants.

Also called NCT01551173

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 436 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01551173
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01551173. Randomized; double masking; primary purpose treatment. Start 2012-01 (registry gives no type); primary completion 2013-05 (actual). Results posted on 2014-06-11.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
Condition
Lipid Metabolism Disorders
Intervention (Drug)
Fluvastatin sodium
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01551173
Content hash
62af8da1a0691b30550b05e79438e00206ea3b12dbf8d406a60295e890b278fe